Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

Who Took Part

The abstract describes 2 patients taking part.

By PubMed's age tags, the people studied were adults, both men and women.

Patients who did not achieve short-term success were evaluated for long-term success at week 9 (end of treatment), 6 months, and 1 year after the start of the study.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

The patients were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

Running at several centres spread the Therapeutic nicotine (patch, non-peptide) study over different clinics and patient groups.

This was a post hoc analysis of a multicenter, double-blind, randomized, placebo-controlled clinical trial in 893 smokers.

What Was Measured

PubMed files the paper under topics including Administration, Cutaneous, Bupropion, Nicotine, Smoking Cessation, Tobacco Use Disorder and Treatment Failure.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2001 (Clinical therapeutics), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.